The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Inclusion Criteria:

• Patients with histological confirmed epithelia ovarian cancer
• Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
• Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
• FFPE tumor tissue available

Exclusion Criteria:

• Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.
• Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator

Patients will be identified at their already planned treatment and or at control visits at the oncology department